Contineum initiated with an Outperform at RBC Capital

RBC Capital analyst Brian Abrahams initiated coverage of Contineum with an Outperform rating and $30 price target. The analyst is optimistic about the long-term prospects of Contineum’s portfolio. The firm believes “solid underlying scientific evidence, pharmacological optimization, and comprehensive clinical work lay strong foundations” for ‘791 and ‘307 to be pursued in several very large-market indications. RBC sees substantial appreciation potential over time for the shares as these assets progress through development.